LT3556350T - Farmacinis preparatas, apimantis priešvirusinį dihidrochinazolino darinį su s konfiguracija 4 pozicijoje - Google Patents

Farmacinis preparatas, apimantis priešvirusinį dihidrochinazolino darinį su s konfiguracija 4 pozicijoje

Info

Publication number
LT3556350T
LT3556350T LTEP19176985.0T LT19176985T LT3556350T LT 3556350 T LT3556350 T LT 3556350T LT 19176985 T LT19176985 T LT 19176985T LT 3556350 T LT3556350 T LT 3556350T
Authority
LT
Lithuania
Prior art keywords
antiviral
configuration
pharmaceutical preparation
dihydroquinazoline derivative
dihydroquinazoline
Prior art date
Application number
LTEP19176985.0T
Other languages
English (en)
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Peter Van Hoogevest
Original Assignee
Aic246 Ag & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3556350(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aic246 Ag & Co. Kg filed Critical Aic246 Ag & Co. Kg
Publication of LT3556350T publication Critical patent/LT3556350T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEP19176985.0T 2012-02-29 2013-02-28 Farmacinis preparatas, apimantis priešvirusinį dihidrochinazolino darinį su s konfiguracija 4 pozicijoje LT3556350T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat

Publications (1)

Publication Number Publication Date
LT3556350T true LT3556350T (lt) 2024-02-26

Family

ID=47757622

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19176985.0T LT3556350T (lt) 2012-02-29 2013-02-28 Farmacinis preparatas, apimantis priešvirusinį dihidrochinazolino darinį su s konfiguracija 4 pozicijoje
LTEP13707000.9T LT2819648T (lt) 2012-02-29 2013-02-28 Farmacinis preparatas, turintis priešvirusinį veiksmingą dihidrochinazolino darinį

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP13707000.9T LT2819648T (lt) 2012-02-29 2013-02-28 Farmacinis preparatas, turintis priešvirusinį veiksmingą dihidrochinazolino darinį

Country Status (37)

Country Link
US (1) US10603384B2 (lt)
EP (3) EP4328218A3 (lt)
JP (1) JP6387486B2 (lt)
KR (1) KR102149561B1 (lt)
CN (2) CN104144678A (lt)
AU (1) AU2013224947B2 (lt)
BR (1) BR112014020946B1 (lt)
CA (1) CA2865203C (lt)
CL (1) CL2014002306A1 (lt)
CO (1) CO7061076A2 (lt)
CY (1) CY1121910T1 (lt)
DE (1) DE102012101680A1 (lt)
DK (2) DK3556350T3 (lt)
EA (1) EA026584B1 (lt)
ES (1) ES2741698T3 (lt)
FI (1) FI3556350T3 (lt)
HK (1) HK1205462A1 (lt)
HR (2) HRP20240197T1 (lt)
HU (1) HUE045949T2 (lt)
IL (1) IL234363B (lt)
IN (1) IN2014MN01892A (lt)
LT (2) LT3556350T (lt)
MA (1) MA35941B1 (lt)
ME (1) ME03448B (lt)
MX (1) MX369666B (lt)
MY (1) MY172310A (lt)
NZ (1) NZ628444A (lt)
PH (1) PH12014501937A1 (lt)
PL (2) PL2819648T3 (lt)
PT (2) PT3556350T (lt)
RS (2) RS59157B1 (lt)
SG (1) SG11201405294XA (lt)
SI (2) SI3556350T1 (lt)
TN (1) TN2014000345A1 (lt)
UA (1) UA111415C2 (lt)
WO (1) WO2013127970A1 (lt)
ZA (1) ZA201405949B (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
CA2916143C (en) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
US11864912B2 (en) 2016-06-03 2024-01-09 Atreya Innovations Private Limited Device for the detection and reliable capturing of the pulse characteristics
MY196966A (en) * 2017-03-06 2023-05-15 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
FR2585705B1 (fr) * 1985-08-05 1989-01-13 Bristol Myers Co Sels de cephalosporine et compositions injectables
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度tcf製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
JP4619545B2 (ja) * 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ アミド誘導体
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
CA2546932A1 (en) * 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
EP1846410B1 (en) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
MX2014010364A (es) 2014-12-05
WO2013127970A1 (de) 2013-09-06
EA201400963A1 (ru) 2015-02-27
ME03448B (me) 2020-01-20
KR102149561B1 (ko) 2020-08-31
LT2819648T (lt) 2019-09-10
TN2014000345A1 (en) 2015-12-21
SG11201405294XA (en) 2014-11-27
CA2865203A1 (en) 2013-09-06
AU2013224947B2 (en) 2017-06-29
PT2819648T (pt) 2019-09-05
EP3556350B1 (de) 2024-01-10
PT3556350T (pt) 2024-02-15
EP3556350A1 (de) 2019-10-23
US10603384B2 (en) 2020-03-31
PL2819648T3 (pl) 2019-10-31
DK3556350T3 (da) 2024-02-12
MA35941B1 (fr) 2014-12-01
ZA201405949B (en) 2021-07-28
JP6387486B2 (ja) 2018-09-12
HRP20240197T1 (hr) 2024-04-26
HRP20191369T1 (hr) 2019-11-01
EP4328218A3 (de) 2024-04-10
SI3556350T1 (sl) 2024-03-29
BR112014020946B1 (pt) 2022-04-05
IN2014MN01892A (lt) 2015-07-10
DE102012101680A1 (de) 2013-08-29
RS59157B1 (sr) 2019-10-31
EP4328218A2 (de) 2024-02-28
US20150133461A1 (en) 2015-05-14
CN104144678A (zh) 2014-11-12
NZ628444A (en) 2016-07-29
HK1205462A1 (en) 2015-12-18
CL2014002306A1 (es) 2014-11-28
RS65137B1 (sr) 2024-02-29
FI3556350T3 (fi) 2024-02-14
EP2819648A1 (de) 2015-01-07
PH12014501937A1 (en) 2014-11-24
MX369666B (es) 2019-11-14
IL234363B (en) 2020-04-30
CA2865203C (en) 2019-11-05
BR112014020946A2 (lt) 2017-06-20
CN110433166A (zh) 2019-11-12
EA026584B1 (ru) 2017-04-28
KR20140130683A (ko) 2014-11-11
PL3556350T3 (pl) 2024-05-06
MY172310A (en) 2019-11-21
JP2015508801A (ja) 2015-03-23
SI2819648T1 (sl) 2019-10-30
ES2741698T3 (es) 2020-02-12
HUE045949T2 (hu) 2020-01-28
CO7061076A2 (es) 2014-09-19
UA111415C2 (uk) 2016-04-25
DK2819648T3 (da) 2019-08-26
CY1121910T1 (el) 2020-10-14
EP2819648B1 (de) 2019-05-29
AU2013224947A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
FI3556350T3 (fi) Antiviraalisesti vaikuttavaa dihydrokinatsoliinijohdannaista, jolla on 4-asemassa S-konfiguraatio, sisältävä farmaseuttinen valmiste
HK1205690A1 (en) Pharmaceutical composition and administration thereof
HRP20181172T1 (hr) Derivati pirazolpirimidina supstituirani na poziciji 4, te njihova uporaba u proizvodnji lijekova
EP2891658A4 (en) PRODRUCE OF TENOFOVIR AND ASSOCIATED PHARMACEUTICAL USES THEREOF
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
SI2655375T1 (sl) Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
SG10201606161UA (en) Albumin Formulation and Use
AP2015008208A0 (en) Pharmaceutical administration forms comprising
HK1208676A1 (en) Novel benzazepine derivative and pharmaceutical use thereof
IL238461A0 (en) 1 hindole-3-carboxamide derivatives and their use as p2y12 inhibitors
EP2835372A4 (en) THIOPHENE [2, 3-D] PYRIMIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
EP2817004A4 (en) BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES
GB201217990D0 (en) Antiviral drug derivatives
GB201210410D0 (en) Improvements in antimicrobial drugs
GB201112578D0 (en) Pharmaceutical preparation and use
GB201121968D0 (en) Antiviral drug derivatives
GB201121966D0 (en) Antiviral drug derivatives